血液系统恶性肿瘤中的分子检测
Molecular Testing in Hematologic Malignancies.
作者信息
Zitella Laura J
机构信息
University of California San Francisco.
出版信息
J Adv Pract Oncol. 2022 Apr;13(3):324-327. doi: 10.6004/jadpro.2022.13.3.29. Epub 2022 May 23.
Molecular testing technologies have been increasingly integrated into clinical research and are essential tools in the care of patients with hematologic malignancies. During this session at JADPRO Live Virtual 2021, Laura J. Zitella, MS, RN, ACNP-BC, AOCN, reviewed key concepts for diagnostic testing with a focus on molecular testing (including cytogenetics, FISH, PCR, and next-generation sequencing) and discussed how to interpret the results for hematologic malignancies to inform prognosis as well as treatment.
分子检测技术已越来越多地融入临床研究，并且是血液系统恶性肿瘤患者护理中的重要工具。在2021年JADPRO现场虚拟会议的本次会议期间，医学硕士、注册护士、成人护理认证护士从业者、肿瘤护理认证护士劳拉·J·齐特拉回顾了诊断检测的关键概念，重点是分子检测（包括细胞遗传学、荧光原位杂交、聚合酶链反应和下一代测序），并讨论了如何解读血液系统恶性肿瘤的检测结果以指导预后和治疗。
Zotero 插件